ERBB2 and rhabdomyosarcoma: A study in rhabdomyosarcoma also underscored the therapeutic potential of simultaneous targeting of IGF-1R and human epidermal growth factor receptor 2 (HER2) to abrogate resistance (Abraham et al., 2011).